netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research

Prestigious award is for the scientists’ work, which led to the first gene therapy for an inherited disease.

Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research, which collectively led to the development and 2017 FDA approval of Luxturnaä, a successful treatment for a type of Leber congenital amaurosis (LCA).  LCA is a genetic cause of childhood blindness.  Their work also demonstrated the potential for future developments in gene therapy for other inherited diseases, and led to the first gene therapy for an inherited human disease.  The RPB-associated awardees include: 

  • Jean Bennett, MD PhD, FARVO, of the University of Pennsylvania School of Medicine. Bennett is the recipient of multiple awards from RPB, including a Career Development Award (1992), Special Scholar Award (2000), Lew R. Wasserman Merit Award (2004) and Senior Scientific Investigator Award (2007).
  • Albert Maguire, MD, of the Children's Hospital of Philadelphia, who received RPB’s Physician-Scientist Award in 2001.
  • Samuel Jacobson, MD, PhD, of the Scheie Eye Institute, University of Pennsylvania School of Medicine, 2000 recipient of the RPB Senior Scientific Investigator Award.
  • William Hauswirth, PhD, of the University of Florida College of Medicine, who received the Senior Scientific Investigator Award in 1997.
  • Robin Ali, PhD, FMedSci, of the Institute of Ophthalmology of the University College of London. Ali has been a member of the RPB Scientific Advisory Panel since 2015.

The five – and two others who will receive the Champalimaud Award – will share a 1 million Euro prize.  The awardees will also present a special lecture at ARVO 2019 in Vancouver.

The António Champalimaud Vision Award is supported by Vision 2020 - The Right to Sight, a global blindness-prevention initiative launched in collaboration with the World Health Organization and the International Agency for the Prevention of Blindness.

 lEARN MORE ABOUT THE AWARD

 

Related News: Feature Story, For the Media, Gene Therapy, Top Story

RPB-SUPPORTED RESEARCHERS WILL BE INTEGRAL PART OF LATEST EFFORT WITHIN NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 

EMERGING VISION SCIENTISTS EDUCATE, THANK CONGRESS FOR RESEARCH APPROPRIATIONS

(NAEVR) held its Fourth Annual Emerging Vision Scientists (EVS) Day on Capitol Hill and twenty early-stage investigators participated.

Read More

 

RESEARCH TO PREVENT BLINDNESS AND LIONS CLUBS INTERNATIONAL FOUNDATION TO CONTINUE LOW VISION RESEARCH AWARD PARTNERSHIP

Research to Prevent Blindness (RPB) and Lions Clubs International Foundation (LCIF) announced today that they will continue their partnership in the RPB/LCIF Low Vision Research Award.

Read More

 

IN THE FUTURE, ALZHEIMER’S MAY BE PREDICTED DURING EYE EXAMS

RPB-funded researchers at Washington University School of Medicine in St. Louis (WUSTL) have found a correlation in 30 older patients between retina thinning and elevated levels of tau and amyloid proteins that are the hallmark of Alzheimer’s disease.

Read More

 

Research to Prevent Blindness and Association of University Professors of Ophthalmology Announce 2018 Recipient of RPB David F. Weeks Award for Outstanding AMD Research

RPB and AUPO announce 2018 recipient of David F. Weeks Award for outstanding AMD research.

Read More

 

Groundbreaking Gene Therapy for Retinal Disease

The first patient receives an FDA-approved gene therapy for inherited retinal disease at Mass. Eye and Ear.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.